Great Lakes Advisors LLC Makes New Investment in Regeneron Pharmaceuticals, Inc. $REGN

Great Lakes Advisors LLC purchased a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 16,928 shares of the biopharmaceutical company’s stock, valued at approximately $10,555,000.

Several other large investors also recently made changes to their positions in the business. Insigneo Advisory Services LLC raised its holdings in shares of Regeneron Pharmaceuticals by 3.0% in the 4th quarter. Insigneo Advisory Services LLC now owns 445 shares of the biopharmaceutical company’s stock worth $343,000 after purchasing an additional 13 shares in the last quarter. Arjuna Capital lifted its stake in Regeneron Pharmaceuticals by 3.2% during the first quarter. Arjuna Capital now owns 457 shares of the biopharmaceutical company’s stock valued at $353,000 after purchasing an additional 14 shares during the last quarter. Guardian Wealth Advisors LLC NC boosted its holdings in Regeneron Pharmaceuticals by 3.3% during the fourth quarter. Guardian Wealth Advisors LLC NC now owns 443 shares of the biopharmaceutical company’s stock worth $342,000 after buying an additional 14 shares in the last quarter. TD Private Client Wealth LLC boosted its holdings in Regeneron Pharmaceuticals by 9.7% during the fourth quarter. TD Private Client Wealth LLC now owns 169 shares of the biopharmaceutical company’s stock worth $130,000 after buying an additional 15 shares in the last quarter. Finally, MCF Advisors LLC grew its position in Regeneron Pharmaceuticals by 50.0% in the fourth quarter. MCF Advisors LLC now owns 45 shares of the biopharmaceutical company’s stock worth $35,000 after buying an additional 15 shares during the last quarter. Institutional investors own 83.31% of the company’s stock.

Insider Activity

In related news, Director Kathryn Guarini sold 400 shares of the stock in a transaction on Monday, August 10th. The stock was sold at an average price of $800.00, for a total transaction of $320,000.00. Following the completion of the sale, the director directly owned 603 shares in the company, valued at approximately $482,400. This trade represents a 39.88% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Arthur F. Ryan sold 200 shares of Regeneron Pharmaceuticals stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $650.15, for a total value of $130,030.00. Following the sale, the director directly owned 17,303 shares of the company’s stock, valued at approximately $11,249,545.45. The trade was a 1.14% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 1,400 shares of company stock worth $1,090,030 in the last ninety days. Corporate insiders own 6.97% of the company’s stock.

Regeneron Pharmaceuticals News Summary

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Leerink raises price target: Leerink Partners increased its REGN price target from $641 to $824, implying modest additional upside. However, the firm retained a “market perform” rating, suggesting limited conviction in a stronger near-term advance. Benzinga analyst price target report
• Neutral Sentiment: Class-action deadline approaches: Several law firms, including Pomerantz, Hagens Berman, Faruqi & Faruqi, and The Schall Law Firm, reminded investors of a September 14, 2026 deadline to seek lead-plaintiff status in a securities lawsuit. These announcements largely repeat previously reported information and do not represent a new financial or regulatory finding. Pomerantz investor alert
• Negative Sentiment: Litigation highlights clinical-trial concerns: The lawsuits allege that Regeneron made misleading statements about clinical differentiation and slowing event accrual in the Phase 3 fianlimab-Libtayo study, potentially understating the risk that the trial would miss its primary endpoint. The trial failure reportedly erased roughly $11 billion in market value and could create ongoing legal costs, reputational risk, and uncertainty around the program’s commercial prospects. The allegations have not been proven. Hagens Berman Regeneron class-action notice

Regeneron Pharmaceuticals Price Performance

NASDAQ REGN opened at $810.24 on Wednesday. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.34 and a quick ratio of 2.78. The firm has a market capitalization of $83.42 billion, a price-to-earnings ratio of 20.03, a price-to-earnings-growth ratio of 1.37 and a beta of 0.21. The company has a 50 day simple moving average of $683.57 and a 200-day simple moving average of $714.66. Regeneron Pharmaceuticals, Inc. has a 52-week low of $541.00 and a 52-week high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $14.29 EPS for the quarter, beating analysts’ consensus estimates of $10.16 by $4.13. The firm had revenue of $4.29 billion for the quarter, compared to the consensus estimate of $3.82 billion. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The firm’s revenue was up 16.7% on a year-over-year basis. During the same period in the previous year, the firm posted $12.81 earnings per share. Equities research analysts predict that Regeneron Pharmaceuticals, Inc. will post 44.25 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, August 31st. Shareholders of record on Tuesday, August 18th will be paid a dividend of $0.94 per share. The ex-dividend date of this dividend is Tuesday, August 18th. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 9.29%.

Analyst Upgrades and Downgrades

REGN has been the topic of several research reports. JPMorgan Chase & Co. dropped their price target on Regeneron Pharmaceuticals from $950.00 to $850.00 and set an “overweight” rating on the stock in a report on Monday, May 18th. Royal Bank Of Canada raised their price objective on Regeneron Pharmaceuticals from $696.00 to $737.00 and gave the stock a “sector perform” rating in a research note on Friday, July 31st. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research report on Wednesday, June 24th. HSBC reduced their target price on Regeneron Pharmaceuticals from $990.00 to $880.00 and set a “buy” rating for the company in a report on Monday, July 6th. Finally, Guggenheim lifted their price target on Regeneron Pharmaceuticals from $1,000.00 to $1,030.00 and gave the stock a “buy” rating in a research note on Monday, August 3rd. Sixteen analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $801.70.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.